Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL298 Target Snapshot

Gastrin/cholecystokinin type B receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,741Compounds
319Assays
6Approved Drugs
2,353.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Gastrin/cholecystokinin type B receptor shows clinical signal disease relevance led by Barrett's esophagus. 4 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P32239. Start with Barrett's esophagus, then reuse UniProt P32239 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Barrett's esophagus, then reuse UniProt P32239 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
Barrett's esophagus

Gastrin/cholecystokinin type B receptor shows clinical signal disease relevance led by Barrett's esophagus. 4 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Barrett's esophagus because it currently carries clinical signal support. Linked drugs include NETAZEPIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Gastrin/cholecystokinin type B receptor as ChEMBL target CHEMBL298, mapped to UniProt P32239. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Gastrin/cholecystokinin type B receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL298
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P32239
Gastrin/cholecystokinin type B receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Gastrin/cholecystokinin type B receptor is the right protein anchor across sources, using UniProt P32239 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Barrett's esophagus is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameGastrin/cholecystokinin type B receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP32239
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGastrin/cholecystokinin type B receptor
UniProt AccessionP32239
Component TypeProtein
Sequence Length447 aa

Gastrin/cholecystokinin type B receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Gastrin/cholecystokinin type B receptor, mapped to UniProt P32239. Sequence length is 447 aa.

Mapped IDP32239
Review nameGastrin/cholecystokinin type B receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Gastrin/cholecystokinin type B receptor shows clinical signal disease relevance led by Barrett's esophagus. 4 more disease programs remain visible in the same review block.

Clinical signal Phase II
Barrett's esophagus
1 linked drug · 1 direct · 1 efficacy
Linked drugNETAZEPIDE
Clinical signal Phase II
carcinoid tumor
1 linked drug · 1 direct · 1 efficacy
Linked drugNETAZEPIDE
Clinical signal Phase II
Zollinger-Ellison Syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugNETAZEPIDE
Clinical signal Phase I
dyspepsia
1 linked drug · 1 direct · 1 efficacy
Linked drugNETAZEPIDE
Clinical signal Phase I
peptic esophagitis
1 linked drug · 1 direct · 1 efficacy
Linked drugNETAZEPIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with Barrett's esophagus because it currently carries clinical signal support. Linked drugs include NETAZEPIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseBarrett's esophagus
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

6
Approved
10
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC501,570.0
KI633.0
EC50142.0
KD8.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL509524 10.68 Ki 0.021 Preclinical
CHEMBL452991 10.39 Ki 0.0407 Preclinical
CHEMBL1121 10.3 EC50 0.05012 Approved
CHEMBL2093059 10.27 IC50 0.054 Preclinical
CHEMBL262894 10.22 Ki 0.06 Preclinical
CHEMBL2110201 10.13 IC50 0.074 Preclinical
CHEMBL324547 10.1 Ki 0.07943 Clinical
CHEMBL432266 10.06 IC50 0.087 Preclinical
CHEMBL49085 10.06 IC50 0.087 Preclinical
CHEMBL4563364 10.03 IC50 0.09333 Preclinical
Distribution

pChEMBL Value Distribution

197
5.0
209
5.5
209
6.0
243
6.5
204
7.0
214
7.5
206
8.0
145
8.5
128
9.0
72
9.5
pChEMBL
Approved Drugs

Approved Drugs

SINCALIDE
CHEMBL1121
Approved 1976
Properties Compare Identifier
PENTAGASTRIN
CHEMBL1328
Approved 1974
Properties Compare Identifier
Assay Landscape

Assay Landscape

319
Total Assays
1,570
Tested Compounds
3
Assay Types
Binding — 281 assays, 1,570 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 99 402 6.9
cell-based format 90 296 7.4
assay format 49 522 6.9
tissue-based format 34 301 6.7
cell membrane format 9 49 7.8
Functional — 37 assays, 185 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 20 64 7.8
assay format 9 82 7.1
tissue-based format 7 39 5.5
organism-based format 1 0 —
Toxicity — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 1 8.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine